Contents
- 1 Amiodarone IV infusion of 0.5 mg/min (720 mg/day) is equivalent to
- 2 Familial hypercholesterolemia in most cases is due to a genetic mutation of the
- 3 ALL of the following reduce PCSK9 activity EXCEPT
- 4 Which of the following is a small interfering mRNA that inhibits the intracellular synthesis of PCSK9.
- 5 PCSK9 Inhibitor
Sodium channel–blocking antiarrhythmic drugs suppress ventricular ectopic beats a recognized risk factor for sudden death after myocardial infarction but also unexpectedly increased mortality threefold but also unexpectedly increased mortality threefold. What is the name of the Trial?
A. GUSTO
B. COMMIT
C. CAST
D. RALES
Amiodarone IV infusion of 0.5 mg/min (720 mg/day) is equivalent to
A. 500 mg/day orally
B. 0.5 to 1 g/day orally
C. 1.0 to 1.5 g/day orally
D. 1.5 to 2 g/day orally
Familial hypercholesterolemia in most cases is due to a genetic mutation of the
A. apoprotein B100
B. PCSK9 genes
C. LDL receptor
D. apoprotein A-I
ALL of the following reduce PCSK9 activity EXCEPT
A. Alirocumab
B. Evolocumab
C. Inclisiran
D. Eptifibatide
Which of the following is a small interfering mRNA that inhibits the intracellular synthesis of PCSK9.
A. Alirocumab
B. Evolocumab
C. Inclisiran
D. Eptifibatide
PCSK9 Inhibitor
Pharmaceutical products available in the United States that reduce PCSK9 activity:
- alirocumab
- evolocumab
- inclisiran.
Alirocumab and evolocumab are fully-humanized monoclonal antibodies.
Inclisiran is a small interfering mRNA that inhibits the intracellular synthesis of PCSK9.
